Here is the work we've done so far
PepVax's late-stage pre-clinical canadidates includes products from Company's Immagene® program, which the Company has licensed to other biotech ventures like Immage Biotherapeutics. The Company's portfolio also includes one promising late-stage pre-clinical candidate, PV103, licensed from The Wistar Institute and two other early-stage candidates from University of Peking, China.
Triple Negative Breast Cancer and Ovarian
MAGE-A is part of the family of cancer testis antigens (CTA). It is found normally expressed within the testis and not in other human tissues. However, it has been found to be overly expressed in several carcinomas, such as, breast, prostate, and colon. Based on SMARTmid™ DNA platform, the lead candidate is currently going through pre-clinical studies for an expected IND filing in 2018.
HCA587 (MAGE-C2) is part of the family of cancer testis antigens (CTA). It is found normally expressed within the testis and not in other human tissues. However, it has been found to be overly expressed in several carcinomas, such as, lung, prostate, and pancreas, ovarian, and colon. Therefore, peptide antigens using in silico methodology has been validated and will make viable immunotherapy candidates.
Retinoblastoma, Prostate, and Hepatocellular Carcinoma
TFDP3 plays a very important role in the control of cell cycle progression. Further experimentation found TFDP3 p53 apoptosis that are induced by E2F1. p53 is a very important tumor marker and therefore, via the manipulation of TFDP3 could be use control the expression of p53 associated with tumor progression. This novel gene has the possibility to play a very important role in the development of a robust DNA vaccine.